Live genetically engineered protozoan vaccine
The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.
1. A method for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host.
2. The method of claim 1 , wherein the protozoan parasite belongs to the phylum Apicomplexa.
3. The method of claim 2 , wherein the protozoan parasite belongs to a genus selected from the group consisting of Plasmodium, Toxoplasma, Neospora, Eimeria, Theileria, Babesia, Cryptosporidium, Sarcocystis , and Leucocytozoon.
4. The method of claim 1 , wherein the vertebrate host is a mammal or a bird.
5. The method of claim 1 , wherein the live protozoan parasite is genetically engineered to delete a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host.